The Europe Breast Cancer screening Market was valued at US$ 1.12 Billion in 2023 and will grow to US$ 11.85 Billion by 2032, with a CAGR of 7.85% from 2024 to 2032. The main factors propelling the European breast cancer market are heightened government support for the integration of new medicines, a greater number of treatments introduced by the top companies in the industry, and enhanced research and development.
Breast Cancer screening Market Overview
More than 2 million new instances of breast cancer were discovered in 2019. Breast cancer is the second most frequent cancer among women worldwide.
Important drivers propelling the market's growth include the rising prevalence of breast cancer, the existence of major competitors in the European breast cancer screening market, and strong research and development. In the UK, over 58,000 women and 380 men receive a breast cancer diagnosis annually. Every year, over 47,000 individuals in England are given a breast cancer diagnosis. Approximately 4,800 individuals in Scotland receive a breast cancer diagnosis annually. Every year, over 2,900 people in Wales receive a breast cancer diagnosis. With a frequency of 565,500 cases in 2019, breast cancer is the most prevalent cancer among women in the European region, and 1 in 8 of these women will have the disease before the age of 85, according to EUROPA DONNA, the European Coalition Against Breast Cancer. As a result, breast cancer often strikes women in their prime, which is expected to fuel market expansion in the years ahead.
The primary causes of the rising incidence of breast cancer are bad lifestyle choices like smoking, eating poorly, getting sick, and having a strong family history. This raises the need for gold-standard mammograms, and other diagnostic imaging tests, blood, and laboratory testing are becoming more and more common. According to the Globocan study, 32,900 new cases of breast cancer were found in Spain in 2019, and 6,500 deaths from the disease were recorded. The demand for routine screening and technological improvement is growing as a result of the rise in breast cancer cases in Spain. To improve the prognosis for breast cancer patients with an early diagnosis, a number of local governments and other healthcare organizations throughout Europe are holding free breast screening events and providing education.
Growth Factors in the Europe Breast Cancer screening Industry
Increased pharmaceutical developments, new product releases by significant industry players, better patient treatment outcomes, higher pharmacological efficacy and effectiveness, and recently developed therapeutics for the condition all contribute to the growth of the breast cancer market.
In addition, there has been a rise in the incidence of breast cancer among individuals due to factors such as decreased exercise, obesity, increased alcohol consumption, menopause, hormone issues, and family histories of cancer, as well as the government's increased support for the introduction of novel treatments and medications into the healthcare sector. Boost government advantages by creating more regulations, such reimbursement guidelines, to enable the general public to benefit from pricey medical procedures. As a result of the introduction of new laws and increased cost-effectiveness, the breast cancer market is driven by revenue growth.
The market is expanding in part because of the increasing number of clinical trials being conducted for the creation and assessment of screening tests.
Another factor fueling the market's expansion is the increase in clinical trials for the creation and assessment of screening tests. For example, a clinical trial supported by the University Medical Center, Utrecht, Netherlands, is anticipated to be finished by April 2023, according to clinicaltrials.gov. In this study, women aged 50-75 who exhibit higher than 75% mammographic density will have their biennial screening with mammography plus MRI compared to mammography alone, to see which is more cost-effective. Growing clinical trials are anticipated to provide market participants with a chance to develop cutting-edge screening tests, which will further propel the market's expansion.
Germany Breast Cancer screening Market Overview:
A significant share of the market is anticipated to be held by Germany because of things like the high incidence of breast cancer and growing awareness campaigns.
For example, in February 2022, the German startup Vara made breast cancer screening more accessible. In order to achieve its mission of giving every woman access to improved breast cancer screening that could save their lives, the firm has hired breast radiologists. Additionally, in October 2022, the Berlin-based startup Vara raised USD 4.8 million (EUR 4.5 million) in order to expand its goal of enabling universal access to data-driven breast cancer screening.
During the forecast period, awareness initiatives in the nation are also anticipated to hasten market expansion. For example, in October 2021, Wefra Life and the nonprofit organization Pink Ribbon Germany launched the 'Breast Cancer Affects Us All' campaign to increase public awareness of breast cancer, foster a sense of community around the issue, and promote breast care. The campaign included a free multilingual app that covers all pertinent aspects of early breast cancer detection and prevention in a multimedia format in seven different languages. Throughout the projection term, these awareness campaigns are anticipated to boost the usefulness of breast cancer screening in the nation.
The country's market is expected to grow faster as a result of the increasing launches by industry participants. For example, in April 2021, FUJIFILM Europe GmbH announced the updated 'Harmony' edition of the Amulet Innovality mammography system. The 'Harmony' version, AWS V9.3, of the Fujifilm Amulet Innovative Mammography system was accessible.
Europe Breast Cancer screening Market Company Overview
Some of the industry leaders seen in the Europe Breast Cancer screening Market Includes AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc.
Europe Breast Cancer screening Market News
Breast Cancer screening Market Overview
More than 2 million new instances of breast cancer were discovered in 2019. Breast cancer is the second most frequent cancer among women worldwide.
Important drivers propelling the market's growth include the rising prevalence of breast cancer, the existence of major competitors in the European breast cancer screening market, and strong research and development. In the UK, over 58,000 women and 380 men receive a breast cancer diagnosis annually. Every year, over 47,000 individuals in England are given a breast cancer diagnosis. Approximately 4,800 individuals in Scotland receive a breast cancer diagnosis annually. Every year, over 2,900 people in Wales receive a breast cancer diagnosis. With a frequency of 565,500 cases in 2019, breast cancer is the most prevalent cancer among women in the European region, and 1 in 8 of these women will have the disease before the age of 85, according to EUROPA DONNA, the European Coalition Against Breast Cancer. As a result, breast cancer often strikes women in their prime, which is expected to fuel market expansion in the years ahead.
The primary causes of the rising incidence of breast cancer are bad lifestyle choices like smoking, eating poorly, getting sick, and having a strong family history. This raises the need for gold-standard mammograms, and other diagnostic imaging tests, blood, and laboratory testing are becoming more and more common. According to the Globocan study, 32,900 new cases of breast cancer were found in Spain in 2019, and 6,500 deaths from the disease were recorded. The demand for routine screening and technological improvement is growing as a result of the rise in breast cancer cases in Spain. To improve the prognosis for breast cancer patients with an early diagnosis, a number of local governments and other healthcare organizations throughout Europe are holding free breast screening events and providing education.
Growth Factors in the Europe Breast Cancer screening Industry
The Market expansion is driven by rising breast cancer incidence
Because breast cancer is becoming more commonplace globally and more individuals are anticipated to require precise and efficient treatment alternatives, the European breast cancer market's compound annual growth rate (CAGR) is increasing. Since breast cancer is one of the most prevalent malignancies worldwide, more people are anticipated to receive diagnoses in the future as a result of improved diagnostics. The development of new technologies with state-of-the-art features for treatments and enhanced treatment efficacy is a key factor driving the market value growth.Increased pharmaceutical developments, new product releases by significant industry players, better patient treatment outcomes, higher pharmacological efficacy and effectiveness, and recently developed therapeutics for the condition all contribute to the growth of the breast cancer market.
In addition, there has been a rise in the incidence of breast cancer among individuals due to factors such as decreased exercise, obesity, increased alcohol consumption, menopause, hormone issues, and family histories of cancer, as well as the government's increased support for the introduction of novel treatments and medications into the healthcare sector. Boost government advantages by creating more regulations, such reimbursement guidelines, to enable the general public to benefit from pricey medical procedures. As a result of the introduction of new laws and increased cost-effectiveness, the breast cancer market is driven by revenue growth.
The market is expanding in part because of the increasing number of clinical trials being conducted for the creation and assessment of screening tests.
Another factor fueling the market's expansion is the increase in clinical trials for the creation and assessment of screening tests. For example, a clinical trial supported by the University Medical Center, Utrecht, Netherlands, is anticipated to be finished by April 2023, according to clinicaltrials.gov. In this study, women aged 50-75 who exhibit higher than 75% mammographic density will have their biennial screening with mammography plus MRI compared to mammography alone, to see which is more cost-effective. Growing clinical trials are anticipated to provide market participants with a chance to develop cutting-edge screening tests, which will further propel the market's expansion.
Germany Breast Cancer screening Market Overview:
A significant share of the market is anticipated to be held by Germany because of things like the high incidence of breast cancer and growing awareness campaigns.
For example, in February 2022, the German startup Vara made breast cancer screening more accessible. In order to achieve its mission of giving every woman access to improved breast cancer screening that could save their lives, the firm has hired breast radiologists. Additionally, in October 2022, the Berlin-based startup Vara raised USD 4.8 million (EUR 4.5 million) in order to expand its goal of enabling universal access to data-driven breast cancer screening.
During the forecast period, awareness initiatives in the nation are also anticipated to hasten market expansion. For example, in October 2021, Wefra Life and the nonprofit organization Pink Ribbon Germany launched the 'Breast Cancer Affects Us All' campaign to increase public awareness of breast cancer, foster a sense of community around the issue, and promote breast care. The campaign included a free multilingual app that covers all pertinent aspects of early breast cancer detection and prevention in a multimedia format in seven different languages. Throughout the projection term, these awareness campaigns are anticipated to boost the usefulness of breast cancer screening in the nation.
The country's market is expected to grow faster as a result of the increasing launches by industry participants. For example, in April 2021, FUJIFILM Europe GmbH announced the updated 'Harmony' edition of the Amulet Innovality mammography system. The 'Harmony' version, AWS V9.3, of the Fujifilm Amulet Innovative Mammography system was accessible.
Europe Breast Cancer screening Market Company Overview
Some of the industry leaders seen in the Europe Breast Cancer screening Market Includes AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc.
Europe Breast Cancer screening Market News
- In January 2023, the government has allotted USD 12.2 million (GBP 10 million) to build 29 new breast cancer screening centers in order to expedite the identification and treatment of breast cancer, according to NHS England's Department of Health and Social Care.
- In September 2022, to improve the collecting of cancer screening data throughout Europe, the European Union (EU) has provided funding for a new research project that the International Agency for Research on Cancer (IARC) has begun. The goal of the CanScreen-ECIS project is to enhance the caliber and reach of cancer screening initiatives throughout Europe by modernizing the current European Cancer Information System (ECIS).
- Mammography Screening Market
- MRI Screening Market
- Ultrasound Screening Market
- Breast Cancer Mammography Screening Population
- Breast Cancer Magnetic Resonance Imaging (MRI) and Ultrasound Screening Population
- Breast Cancer Screening Market
- Mammography Screening Market
- Magnetic Resonance Imaging (MRI) Screening Market
- Ultrasound Screening Market
- United Kingdom
- France
- Germany
- Italy
- Spain
- Switzerland
- Norway
- Netherlands
- Overviews
- Key Person
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
5. Europe Breast Cancer Screening Population Analysis
6. Europe Breast Cancer Screening Market Analysis
7. Europe Breast Cancer Screening Population Share Analysis
8. Europe Breast Cancer Screening Market Share Analysis
9. United Kingdom
10. France
11. Germany
12. Italy
13. Spain
14. Switzerland
15. Norway
16. Netherlands
17. Porter’s Five Forces
18. SWOT Analysis
19. Company Analysis
Companies Mentioned
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 240 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 1.03 Billion |
| Forecasted Market Value ( USD | $ 2.21 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 6 |
